National Foundation for Cancer Research scientist Michael Sporn is working on a new class of anti-cancer drugs for the prevention of pancreatic cancer. Sporn, who is known at NFCR as "the father of chemoprevention," and his team at Dartmouth Medical School, have designed and synthesized triterpenoids — synthetic compounds that target and inhibit biological processes like inflammation, which play a role in the formation of the disease. "Recently, the researchers demonstrated that the triterpenoids, CCDO-Me and CCDO-EA, inhibited important inflammatory molecules in pancreatic cell lines and slowed the development of the harmful effects of pancreatic cancer in laboratory models that closely resemble the disease in humans," the Foundation says. Now the researchers are working on figuring out the mechanism by which triterpenoids work, and whether they can be used with standard pancreatic cancer therapies to make them more effective.
Battling Pancreatic Cancer
Feb 17, 2011